div class="xn-content">
CAMBRIDGE, England, March 14, 2012 /PRNewswire/ -- Mundipharma International has appointed Paul Medeiros to head its corporate and business development operations. In this position, Mr. Medeiros will join the Executive Leadership Team and play a critical role in extending and expanding avenues for corporate growth within Mundipharma’s European independent associated companies, many of which are growing faster than any other midsized pharmaceutical companies in the market.
Mr. Medeiros brings over 19 years of experience in biopharmaceutical business development and commercialization and a significant track record of success in technology acquisitions, in- and out-licensing, and strategic alliance development across a therapeutic areas. He most recently served as Senior Vice President and Chief Business Officer at AVI BioPharma, a technology-innovating developer of RNA-based therapeutics for rare diseases. In that role, he was responsible for all business development and licensing activity, establishment of academic and commercial research collaborations, product portfolio planning and corporate strategy development. At AVI, he was instrumental in obtaining over $300 million in non-dilutive collaboration funding for the company. Previously, Mr. Medeiros served as Vice President, Global Licensing and Strategic Alliances for Schering-Plough, where he led worldwide product licensing and strategic partnering initiatives in specialist product categories. Mr. Medeiros began his biopharmaceutical career at Merck & Company, where he held positions in field sales, new product planning and worldwide marketing.
“Paul’s deep experience and network in the pharma industry, combined with his entrepreneurial mind-set and nuanced understanding of the business, will be essential for Mundipharma’s continued growth,” said Antony Mattessich, Regional Director, Mundipharma Europe. “We are thrilled to add his energy and expertise to our team, and we look forward to working with him to build stronger partnerships worldwide.”
“Mundipharma’s culture and approach to business are unique in the pharmaceutical industry. I am genuinely excited to be joining such an ambitious, growing organisation,” said Mr. Medeiros.
Paul Medeiros holds an A.B. with honours from Brown University and an M.B.A. from Columbia Business School. He is a member of the Licensing Executives Society and is a Certified Licensing Professional.
About Mundipharma International Limited
The Mundipharma/Napp/Norpharma independent associated companies are privately owned companies and joint ventures covering the world’s pharmaceutical markets. The companies worldwide are dedicated to bringing to patients with severe and debilitating diseases the benefits of novel treatment options in fields such as severe pain, haemato-oncology and respiratory disease. For more information: www.mundipharma.co.uk
SOURCE Mundipharma International Limited
